Skip to main content
. 2017 Dec 27;2(1):1–9. doi: 10.1182/bloodadvances.2017013334

Figure 3.

Figure 3.

Outcome of high-risk patients. (A) Standard- and (B) high-risk patients. Bortezomib arm: purple, no subclone; red, with subclone. Thalidomide arm: green, no subclone; blue, with subclone. Colored numbers below the plots represent uncensored patients at the respective time point.